Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000298227 is an annotated transcript on the opposite (antisense) strand of the TOR1B gene. It is classified as a "novel transcript," suggesting it is a predicted or experimentally identified RNA that does not encode a protein and has unknown or uncharacterized function. There is no evidence that this transcript acts as a receptor, enzyme, transporter, or other classical drug target. No information is available regarding its involvement in human disease, molecular pathways, drug interactions, or biomarker utility. It should not be considered a validated therapeutic target; its primary relevance is as a genomic feature adjacent to the protein-coding gene TOR1B. This entry likely represents computational annotation rather than a validated biological molecule or therapeutic target. Therefore, it should not be used in structured databases for drug target analyses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to TOR1B.